Keywords: Rheumatoid arthritis, Biologicals, Roche, Chugai, Actemra, Roctemra, AstraZeneda, Pfizer, Decision Resources

Uptake of alternative biologics such as Roche/Chugai's Actemra/RoActemra will erode RA market share of TNF-alpha inhibitors through 2019

Article | 30 July 2010

Print This

In the rheumatoid arthritis (RA) drug market, the uptake of alternative biologics such as Roche/Chugai's Actemra/RoActemra (tocilizumab) will ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in